Life Science Intelligence

Industry leaders from Baxter International and top medtech innovators join moderator Joe Mullings to discuss the strategic shift toward “Build to Buy” models shaping the future of healthcare investments and acquisitions. For more information visit here:  https://www.lifesciencemarketresearch.com/videos/new-era-build-to-buys-lsi-usa-25  

Diana brings 23 years of venture capital experience and previously co-founded another successful venture capital firm called 360 Capital. Alessio, with an engineering background, co-founded Panakes in 2015 after working as a research engineer at Sofinnova Partners. Throughout the episode, Diana and Alessio provide valuable insights into the evolving landscape of medtech investing, shedding light on the complexities, challenges, and opportunities in the field. For more information visit here:  https://podcast.lifesciencemarketresearch.com/episode/ep1-transatlantic-investing-and-fund-ii-strategy-with-panakes-partners

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure $164M in new funding, receive regulatory clearances, achieve clinical milestones, and much more on the road to  LSI Asia  ’25 in Singapore (June 10–13). AMT Medical Raised $25 million in Series B funding to accelerate the development of the ELANA® Heart Bypass System, a sutureless, minimally invasive alternative to open-heart coronary artery bypass surgery. The company aims to reduce complications, enable robotic compatibility, and cut procedure costs by over 50% with a standardized, beating-heart approach that eliminates the need for sternotomy or heart-lung machines. Axoft Completed the first four cases in its first-in-human clinical study of the Fleuron™ implantable brain-computer interface (iBCI), demonstrating safe implantation and high-resolution neural recordings. The ultrasoft iBCI captured stable single-neuron activity and a biomarker of consciousness, valid...

Under the direction of Co-Founder and CEO Dr. Oriol Iborra Egea, NIMBLE Diagnostics is creating a new frontier in implant monitoring and vascular care. With a non-invasive, microwave-based diagnostic device designed to monitor implanted stents in real time, NIMBLE is solving a long-standing blind spot in cardiovascular care: knowing what’s happening inside a stent without having to go back inside the body. “We implant a stent, we send the patient home, and we assume everything’s fine — until it’s not,” said Iborra. “We’ve built a way to monitor that stent non-invasively, quickly, and safely — before a serious event occurs.” From a research project in Barcelona to a fast-moving medtech startup with international ambitions, NIMBLE Diagnostics is on a mission to redefine how clinicians follow up with patients after stent implantation — and to prevent life-threatening complications before they happen. Origin Story NIMBLE Diagnostics was born from a collaborative research effort among sever...

The U.S. medtech market continues to be a dominant force globally, representing over 45% of the worldwide medtech revenue as of 2025. Despite recent concerns and headlines suggesting uncertainty, a deeper dive into the numbers tells a different story: one of resilience and steady expansion. Thanks to growing  surgical procedure volumes  and significant investments in innovation, the United States remains at the forefront of medtech development. In this article, we’ll explore the factors driving growth, key statistics, and the market’s long-term outlook for  medtech companies . U.S. Medtech Market Resilience Amidst Challenges For the past several decades, the United States has remained the largest market for medical devices worldwide. Its dominance in the field is attributed to several factors: a robust ecosystem of research and development, a highly engaged healthcare workforce, and the adoption of cutting-edge technologies like surgical robotics and AI-powered diagnostic...

Soltanianzadeh’s medtech journey has taken him from start-up entrepreneur, to investor, to CEO of CardiaCare: an innovative AI-based neuromodulation therapy company working to revolutionize atrial fibrillation treatment. In the midst of a Series A raise, he will be presenting at the March LSI USA ‘25 event in Dana Point, CA. For more information visit here:  https://mega.nz/file/LTxAHJII#mNylAswp3i9PhxvgGpM2f_pQtN9BnWR5z9rQQK2cluU  

  Achieved ISO 13485 certification, the globally recognized standard for quality management systems for medical devices. The accreditation strengthens the company’s manufacturing readiness for its 4Degra bioabsorbable resin platform, supporting its commercial strategy and accelerating regulatory pathways toward clinical deployment. For more information visit here:  https://medium.com/@lifesciencemarketresearch/the-weekly-recap-4-11-25-lsi-alumni-achievements-driving-medtech-and-healthtech-forward-386e389bab3a

 The LSI Alumni 2025 Funding Report is now updated with all deals from Q1. In Q1 of 2025, LSI Alumni raised over $1.37 billion across 45 deals. Our quarterly Alumni Funding Report features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies. For more information visit here:  https://medium.com/@lifesciencemarketresearch/the-lsi-alumni-funding-report-q1-2025-life-science-intelligence-baebf69af4df

Appointed Shlomi Nachman as Chairman of the Board to help advance its mission of transforming stroke prevention for patients with atrial fibrillation. Nachman brings over 25 years of medtech leadership, including senior roles at Johnson & Johnson, and will guide the company’s growth as it scales its implant-free, vacuum-based LAA occlusion system. For more information visit here:  https://medium.com/@lifesciencemarketresearch/the-weekly-recap-4-4-25-lsi-alumni-achievements-driving-medtech-and-healthtech-forward-5f1ddc63723d  

In March 2025, Alcon made headlines with its acquisition of LENSAR, Inc. for up to $430 million. The deal signals Alcon’s ongoing commitment to advancing robotic platforms in ophthalmology, particularly in robotic eye surgery. This acquisition allows Alcon to strengthen its leadership in cataract surgery and expand its portfolio in the growing field of robotic systems for eye surgery. For more information visit here:  https://www.slideshare.net/slideshow/robotic-eye-surgery-and-alcon-s-strategic-acquisition/277812846  

Few people understand the evolution of arthroscopic surgery like Justin Anderson. With a career spanning nearly three decades, Anderson has been instrumental in creating entirely new surgical markets, from pioneering temperature-controlled radiofrequency technology for arthroscopy to developing the first knotless tensionable suture anchor for rotator cuff repair from shape memory nitinol to flying all around the world creating a market for the future of value-based rotator cuff and soft tissue repair…“anchorless” solutions, he commercialized that obviate the need for suture anchors, the single highest cost driver in rotator cuff repair globally. With six exits and two IPOs to his credit, Anderson’s deep domain experience is noteworthy. For more details visit here:  https://medium.com/@lifesciencemarketresearch/the-memo-ai-driven-tensor-surgical-redefines-orthopedic-soft-tissue-repair-with-anchorless-dce77d61e2c0  

The medtech landscape is constantly evolving, with startups at the forefront of bringing innovative solutions to market. As part of our coverage from the recent LSI USA ’25 event, we’ve highlighted five standout medtech startups to keep an eye on in 2025. These companies are shaping the future of healthcare with breakthrough technologies, and their presentations at LSI USA provided a glimpse into the promising solutions they are bringing to the table. For more information visit here:  https://medium.com/@lifesciencemarketresearch/medtech-startups-to-watch-in-2025-analyst-perspective-fe1a35b8a419